西藏药业新活素继续纳入国家医保药品目录

Core Viewpoint - Tibet Pharmaceutical announced that its wholly-owned subsidiary Chengdu Nodi Kang Biopharmaceutical Co., Ltd. has had its recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan) continuously included in the medical insurance directory and adjusted to the regular directory [1] Group 1 - Xinhuasuan is classified as a new biological product and is indicated for intravenous treatment of acute decompensated heart failure patients experiencing dyspnea at rest or with minimal activity [1] - As a gene-engineered drug for treating acute heart failure, Xinhuasuan can rapidly improve symptoms and signs of heart failure, enhance patients' quality of life, reduce hospitalization costs, and shorten hospital stays [1]